Top Page
Aurora Spine
(ASG)
Aurora Spine (ASG) vs. iShares MSCI Canada ETF (EWC)
Aurora Spine Business Overview & Revenue Model
Aurora Spine Earnings Call Summary
Aurora Spine Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.56M | 14.52M | 14.88M | 10.54M | 8.65M |
| Gross Profit | 10.63M | 8.21M | 7.81M | 4.83M | 3.47M |
| EBITDA | 179.90K | -446.20K | -469.27K | -1.90M | -573.86K |
| Net Income | -1.00M | -1.68M | -1.50M | -2.36M | -232.09K |
Balance Sheet | |||||
| Total Assets | 11.67M | 11.99M | 10.12M | 10.56M | 7.16M |
| Cash, Cash Equivalents and Short-Term Investments | 775.62K | 766.83K | 423.40K | 3.17M | 1.71M |
| Total Debt | 3.67M | 3.65M | 2.97M | 2.38M | 2.34M |
| Total Liabilities | 7.28M | 6.69M | 5.81M | 4.99M | 3.87M |
| Stockholders Equity | 4.40M | 5.30M | 4.32M | 5.57M | 3.28M |
Cash Flow | |||||
| Free Cash Flow | 266.47K | -1.41M | -2.43M | -2.85M | -245.07K |
| Operating Cash Flow | 904.33K | -935.06K | -1.56M | -2.13M | 309.57K |
| Investing Cash Flow | -484.32K | -479.13K | -873.21K | -720.61K | -554.64K |
| Financing Cash Flow | -361.22K | 1.76M | -318.15K | 4.31M | 1.51M |
Aurora Spine Technical Analysis
Aurora Spine Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | C$106.00M | ― | -8.34% | ― | 0.69% | -95.27% | |
55 Neutral | C$24.20M | ― | -23.87% | ― | 18.97% | 17.57% | |
54 Neutral | C$243.43M | ― | -66.14% | ― | 51.21% | 15.33% | |
51 Neutral | C$48.91M | ― | -291.48% | ― | -8.63% | 7.04% | |
50 Neutral | C$23.38M | ― | -163.62% | ― | 113.85% | 11.38% | |
46 Neutral | C$194.85M | -4.28 | -8.56% | 2.84% | 13.52% | -1.74% | |
44 Neutral | C$21.68M | ― | 207.08% | ― | 280.56% | -7.28% |
Aurora Spine Corporate Events
Aurora Spine has achieved a significant milestone with its DEXA-C system, having been used in over 1,500 cervical spine surgeries across the United States. This accomplishment highlights the growing adoption and effectiveness of their DEXA Technology, which is designed to match patient bone density and improve surgical outcomes. The company is preparing to launch a new product, the DEXA-L, in Q4 2025, which will expand their portfolio and further address the challenges of spinal fusion in patients with low bone density. This advancement positions Aurora Spine as a leader in patient-matched spinal care, offering innovative solutions for diverse patient needs.
Aurora Spine has achieved a significant milestone with its SiLO™ Sacroiliac Joint Fusion System, which has been used in over 2,500 procedures across the United States. This accomplishment highlights the growing adoption of their minimally invasive technology, which is designed to improve patient outcomes and recovery times. The company’s continued innovation and expansion in the U.S. market, along with positive feedback from the surgical community, underscore its leadership in the field of spinal solutions.
Aurora Spine Corporation announced its participation in the Lytham Partners Spring 2025 Investor Conference, where it will present a webcast and host one-on-one meetings with investors. This participation underscores Aurora Spine’s commitment to engaging with investors and stakeholders, potentially enhancing its market presence and investor relations.
Aurora Spine Corporation announced record financial results for the first quarter of 2025, with a 10% increase in revenue compared to the previous year. The company received FDA clearance for its AERO Facet Fusion System and reported significant sales growth in its DEXA-C cervical implant. Aurora Spine is optimistic about future growth, driven by its robust R&D efforts and upcoming product launches, including the DEXA-L series and the AERO system, which are expected to enhance patient outcomes and expand market reach.
Aurora Spine Corporation announced the release schedule for its first quarter fiscal 2025 financial results, which will be filed on May 21, 2025, with a press release and investor conference call to follow on May 22, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
Aurora Spine Corporation reported a record revenue of $17.6 million for fiscal year 2024, marking a 21% increase from the previous year. The company’s financial success was driven by a 135% surge in sales of the SiLO-TFX SI joint implant, expansion of its internal sales force, and increased margins. The company also achieved its first annual positive EBITDAC and is poised for further growth with the recent FDA clearance of its new AERO product platform.
Aurora Spine Corporation announced the release of its fourth quarter and fiscal year 2024 financial results, scheduled for April 28, 2025. The company also clarified an error in its management information circulars regarding its stock option plan, ensuring the correct version will be included in future shareholder meeting materials.
Aurora Spine has announced the resignation of James Snow from its Board of Directors as he transitions to the role of Regulatory Affairs and Quality Assurance Manager within the company. This move highlights Snow’s commitment to Aurora Spine’s future and his belief in the company’s innovative technologies, as he aims to enhance compliance and quality across their product portfolio.